Deep Dive: Page 2

Industry insights from our journalists


  • Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip

    ‘The music stopped’: Biotech rout leaves drug startups grounded as demand slumps for IPOs

    For the first time in years, biotechs no longer had an easy path onto Wall Street, a market reversal that could change what the next generation of young drugmakers looks like.

    Ben Fidler • Feb. 7, 2022
  • An illustrated image of clinical development for a BioPharma Dive 2021 outlook story
    Image attribution tooltip
    Kendall Davis/BioPharma Dive
    Image attribution tooltip

    10 clinical trials to watch in the first half of 2022

    Biotech stocks ended 2021 in a slump. But positive results from eagerly anticipated studies in breast cancer, schizophrenia and Alzheimer's disease could help turn the sector's fortunes around.

    Ben Fidler • Updated Jan. 6, 2022
  • Cedars-Sinai lab technicians conduct ALS research.
    Image attribution tooltip
    Permission granted by The ALS Association
    Image attribution tooltip

    On the hunt for new ALS drugs, researchers see progress, and a long road ahead

    The fatal nerve disease has few treatments. But despite continued setbacks, drug developers are hopeful that genetic technologies and a better understanding of biology will bring new options in the not-too-distant future

    Jacob Bell • Dec. 13, 2021
  • A photo of Sekar Kathiresan, CEO of Verve Therapeutics
    Image attribution tooltip
    Seth Babin/BioPharma Dive
    Image attribution tooltip

    Heart attacks struck Sek Kathiresan's family. He's devoted his life to stopping them.

    After several family members had early heart attacks, Kathiresan vowed to understand why they happen. His research journey has changed medical practice and led to a new biotech startup, Verve Therapeutics, that seeks to prevent them.

    Ben Fidler • Nov. 29, 2021
  • Dr. Jason Comander performs the first Luxturna surgery post-FDA approval on March 20, 2018 at Massachusetts Eye and Ear.
    Image attribution tooltip
    Permission granted by Ed Shipman for Mass Eye and Ear
    Image attribution tooltip

    Years later, a first-of-its-kind treatment shows the power, and limits, of gene therapy

    Luxturna, approved four years ago as the first gene therapy for an inherited disease in the U.S., is improving sight and quality of life for several of the patients who received it.

    Shoshana Dubnow • Nov. 15, 2021
  • A stylized illustration of a "patent thicket" for Jonathan Gardner's Nov. 1 story on Amgen's Enbrel.
    Image attribution tooltip
    Adeline Kon / BioPharma Dive/BioPharma Dive
    Image attribution tooltip

    A three-decade monopoly: how Amgen built a patent thicket around its top-selling drug

    Through high-stakes litigation, aggressive patenting practices and a bit of luck, Amgen will likely stretch Enbrel's monopoly until 2029, more than 30 years after it was approved.

    Jonathan Gardner • Nov. 1, 2021
  • Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    A play-by-play of the FDA's meeting on Pfizer's vaccine for kids

    Experts on the agency's panel dug into questions on the vaccine's safety in younger children, as well as uncertainty over how widely it should be used. Catch up on the discussion here. 

    Ben Fidler, Shoshana Dubnow and Jonathan Gardner • Updated Oct. 26, 2021
  • Vertex CEO Reshma Kewalramani
    Image attribution tooltip
    Permission granted by Vertex Pharmaceuticals
    Image attribution tooltip

    'This is the time to double down': Top Vertex executives defend research plan as pressure builds

    A series of setbacks has led to criticism of the storied biotech's bid to diversify. But Vertex intends to stay the course, its CEO and top scientist say.

    Ben Fidler • Sept. 22, 2021
  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip

    Biotech M&A is on the upswing. Track the latest deals here.

    Eleven private biotech companies have been acquired through May, putting 2024 on pace to be a particularly strong year for startup M&A.

    Ned Pagliarulo, Jacob Bell and Julia Himmel • Updated May 29, 2024
  • An illustration of CRISPR-cas9 gene editing
    Image attribution tooltip
    del Aguila III, Ernesto. (2018). "CRISPR Cas9" [Illustration]. Retrieved from Flickr.
    Image attribution tooltip

    Intellia, with first results, delivers a 'landmark' for CRISPR gene editing

    Results published in The New England Journal of Medicine offer the first clinical evidence that CRISPR gene editing inside the body can be safe and effective, a culmination of years of scientific research.  

    Ben Fidler • June 26, 2021
  • An illustrated image of clinical development for a BioPharma Dive 2021 outlook story
    Image attribution tooltip
    Kendall Davis/BioPharma Dive
    Image attribution tooltip

    8 key clinical trials to watch for the rest of 2021

    The next six months could feature clinical milestones for CRISPR gene editing, the treatment of COVID-19 and gene-targeted cancer therapy.

    Ben Fidler • June 21, 2021
  • Image attribution tooltip
    Brian Tucker / BioPharma Dive
    Image attribution tooltip

    'The lights are no longer green': Antitrust regulators reassess pharma deals

    The FTC and its counterparts abroad are rethinking their approach to drugmaker acquisitions. Past scrutiny offers clues to where they may look next.

    Jonathan Gardner • June 10, 2021
  • A photo of a Biogen building
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    A first-of-its-kind Alzheimer's drug raises heavy questions around who will and won't get it

    Biogen priced its newly approved medicine Aduhelm at an average cost of $56,000 a year, adding affordability to other barriers patients may face. 

    Jacob Bell • June 8, 2021
  • Ajay Purohit, a Biogen employee, points to brain scans of people with Alzheimer's
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    In historic move, FDA approves a closely watched and controversial Alzheimer's drug

    The decision cleared the way for what many predicted would become a lucrative treatment. But a high price and controversy over whether Biogen's Aduhelm benefits patients weighed heavily on the drug's launch.

    Jacob Bell • Updated June 7, 2021
  • A picture of the street sign stating "Wall Street." American flags drape over a nearby building
    Image attribution tooltip
    Kena Betancur via Getty Images
    Image attribution tooltip

    Trump tax law cut what US drugmakers owed. Now they fear an increase.

    The 2017 law saved pharmaceutical companies billions of dollars, BioPharma Dive found. Executives are now fiercely opposing tax hikes proposed by President Biden, claiming they've since boosted domestic investment. 

    Jonathan Gardner • May 17, 2021
  • A sign at Gilead Sciences
    Image attribution tooltip
    Permission granted by Gilead Sciences
    Image attribution tooltip

    How Gilead finally spent its money

    This year, the biotech spent about $27 billion trying to become a leader in cancer research. Executives who spoke to BioPharma Dive said there's still work to be done.

    Jacob Bell • Nov. 24, 2020
  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Alumis outlined plans for an offering that, if successful, would be the third by an immune drug developer this year.

    Ben Fidler and Gwendolyn Wu • Updated June 9, 2024
  • A photograph of Cheryl and Jase Yoder, with family
    Image attribution tooltip
    Permission granted by Cheryl Yoder
    Image attribution tooltip

    From no drugs to 3: Patients with spinal muscular atrophy now face hard choices

    The availability of three vastly different, cutting-edge medicines for the rare disease has put patients, families and doctors in an unfamiliar position.

    Jonathan Gardner • Oct. 5, 2020
  • An illustration for BioPharma Dive's 2020 report on drugmaker executive compensation
    Image attribution tooltip
    Danielle Ternes/BioPharma Dive
    Image attribution tooltip

    How biotech and pharma companies pay their CEOs, and their workers

    The median CEO of 231 drug companies analyzed by BioPharma Dive earned 50% more last year than in 2017, a leap that far outpaced the more modest pay gains among employees.

    Ned Pagliarulo • Sept. 9, 2020
  • A scientist in a laboratory at Relay Therapeutics
    Image attribution tooltip
    Permission granted by Relay Therapeutics
    Image attribution tooltip

    Relay Therapeutics set out to change how drugs are designed. Can it continue what Vertex began?

    Vertex pioneered a more precise way of developing drugs. Relay, which has raised nearly $1 billion since its founding, thinks it can go one step further. 

    Ned Pagliarulo • Aug. 24, 2020
  • Image attribution tooltip
    Danielle Ternes/BioPharma Dive
    Image attribution tooltip

    A cure for hemophilia seemed closer than ever. For many patients, it’s now further out of reach

    The surprise rejection of BioMarin's hemophilia A gene therapy delayed a decades-long mission to fix the rare bleeding disorder.

    Jacob Bell • Updated Aug. 19, 2020
  • lonza-roche-vacaville-ca-manufacturing-site
    Image attribution tooltip
    Courtesy of Lonza
    Image attribution tooltip

    Vaccines can end the coronavirus pandemic. Will every country get them?

    Scientists around the world are racing to develop a coronavirus vaccine. But the factories slated to make the leading candidates are concentrated in a handful of countries, raising concerns about global access.

    Jonathan Gardner • June 23, 2020
  • A custom header image for BioPharma Dive's tracker of coronavirus vaccine development.
    Image attribution tooltip
    Brian Tucker/BioPharma Dive
    Image attribution tooltip

    Coronavirus vaccines are rolling out quickly. Here's where the pipeline stands.

    Fuller data in hand, Pfizer and BioNTech plan to soon seek full U.S. approval for their vaccine in 12- to 15-year-olds. 

    Ned Pagliarulo, Jonathan Gardner, Shoshana Dubnow, Ben Fidler and Nami Sumida • Updated Nov. 24, 2021
  • Image attribution tooltip
    Yujin Kim/BioPharma Dive
    Image attribution tooltip

    Venture capital found its footing in biotech. Then came the virus.

    There's been no better time for venture firms to invest in drug startups than the past few years. But when a virus upended the world, it raised new questions about what types of investors and investments would succeed moving forward.

    Jacob Bell • May 26, 2020
  • Electron microscope image of SARS-CoV-2, isolated from a patient in the U.S.
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel coronavirus SARS-CoV-2" [Microscope image]. Retrieved from https://www.flickr.com/photos/nihgov/49565158908/in/album-72157713108522106/.
    Image attribution tooltip

    A closer look at the race to develop antibody drugs for COVID-19

    Eli Lilly, Regeneron and China's Junshi are now testing antibody drugs in clinical trials, while others are close behind. Here's why they will matter.

    Ben Fidler • May 12, 2020